EGPA is an acquired immune-mediated condition. No causative genetic variants are documented in this packet, consistent with its classification as an acquired vasculitis. The underlying immunological drivers of eosinophil accumulation and vessel wall inflammation remain under investigation.

Specific diagnostic methods are not detailed in this packet. EGPA diagnosis is pursued through clinical evaluation of the characteristic triad and related findings, though the precise diagnostic framework is not documented in the available packet data.

Two FDA-approved treatments are documented in this packet for EGPA. Mepolizumab (brand name NUCALA), an anti-interleukin-5 biologic therapy, received FDA approval via BLA on June 6, 2019, and carries an active market status. Benralizumab (brand name FASENRA), also an FDA-approved biologic, received BLA approval and carries an active market status. Both agents target the eosinophilic component of the disease. Additional therapeutic candidates are under investigation across 19 active clinical trials documented in this packet.

Prognosis data are not documented in this packet. Outcomes in systemic vasculitis are generally influenced by the extent of organ involvement and the response to treatment, though specific prognostic data for EGPA are not available in the certified packet fields.

Nineteen active clinical trials for EGPA are documented in this packet. The research landscape includes 240 classified publications, with review and meta-analysis representing the dominant publication type. Biomarker research and recent trial publications are documented as part of the active scientific landscape for this condition.